


USSN 10/091,232

OFFICIAL
CT 2666 NPRemarks

Pursuant to the Examiner's three-way restriction requirement of March 31, 2003, Applicants elected Group I which is directed to compounds and compositions of Formula (I). Additionally, Applicants were required to elect a single disclosed species. Applicants elected (1*S*,2*S*)-*trans*-2-[5-cyanoindol-3-yl]-1-(*N,N*-dimethylaminomethyl)-cyclopropane which is Example 5 on page 39 of the specification.



(1*S*,2*S*)-*trans*-2-[5-cyanoindol-3-yl]-1-(*N,N*-dimethylaminomethyl)-cyclopropane

Accordingly, the claims for the instant application were amended to reflect the elected subject matter. Claims 1-3, 6, 7, 9, 11, 13, 14, 16, 17, 19, 21, 22, 27-30 and 40-42 are among those that read on the elected species and remained in consideration and objected to as being drawn in part to non-elected subject matter. In the instant Amendment and Reply, Applicants respectfully request *inter alia* that claim 1, 40 and 41 be amended, claims 49-65 be added as described hereinbefore. Support for amending or adding claims can be found in the embodiments, the examples or in the original claims upon which the re-presented claims are based. No new matter has been added.

In Examiner's May 19, 2003 Office Action, a "generic concept of the elected subject matter" was identified based upon the elected species. Applicants' understanding of said generic concept is that it comprises a "[c]ompound of formula I, of claim 1" having the following additional limitations, "J is O; G is N; G¹ is CH" and "R¹R⁵ are as defined, except that they don't represent a heterocyclic group or and R¹R⁵ are not further substituted by a heterocyclic group." The Examiner noted that "[c]laims drawn solely to the elected invention as identified supra, would appear allowable." Applicants have amended claims 1, 40 and 41 and added claims 49-60 to reflect the scope of the generic concept of elected subject matter as described hereinabove.

USSN 10/091,232

OFFICIAL
CT 2666 NP

Moreover, pursuant to MPEP 809.04 and Examiner's notice regarding rejoinder of claims, Applicants have reintroduced method of use claims (61-65) which include all the limitations of any elected composition claims (linking claims) that have appeared allowable to the Examiner. Therefore, Applicants respectfully request that the objections to claims 1-3, 6, 7, 9, 11, 13, 14, 16, 17, 19, 21, 22, 27-30 and 40-42 be withdrawn.


Applicants wish to bring to the Examiner's attention that an IDS was filed on June 26, 2002; a Supplemental IDS was filed on July 11, 2002 followed by an additional Supplemental IDS filed on June 23, 2003.

Applicants respectfully submit that the application is in condition for allowance and maintain the right to file divisional application(s) on non-elected subject matter. The Commissioner is authorized to withdraw an fees from Deposit Account 19-3880.

Dated: 7/11/03

Bristol-Myers Squibb Company
5 Research Parkway, P.O. Box 5100
Wallingford, CT 06492-7660
Phone: (203) 677-7268
Facsimile: (203) 677-6900

Respectfully submitted,


Shah R. Makujina
Attorney for Applicant
Registration No. 41,174